
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is poised for positive financial performance driven by the growing market for respiratory care, underpinned by an increasing diagnosis of sleep apnea and demographic trends such as an aging population and rising obesity rates. The company's revenue from masks and other products in the U.S., Canada, and LATAM has demonstrated a strong year-over-year growth of 12%, indicating robust demand and market share gains in these regions. Furthermore, ResMed's strategy of returning cash to shareholders through increased dividends and an aggressive share repurchase program, while simultaneously investing in operational growth, reflects a strong commitment to enhancing shareholder value amidst anticipated revenue growth.
Bears say
The financial outlook for ResMed is negatively influenced by the potential disruption from GLP-1 drugs, which are expected to impact the future volumes of positive airway pressure (PAP) devices and masks. Despite the company's efforts to differentiate through digital health innovations and its current market outperformance, concerns regarding the impact of GLP-1 drug uptake on growth may hinder revenue growth in the medium term. As ResMed generates a significant portion of its revenues from the Americas, any disruption in key product categories could pose risks to its financial stability and market positioning.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares